1. 方法論と範囲
1.1. 調査方法
1.2. 調査目的と調査範囲
2. 定義と概要
3. エグゼクティブ・サマリー
3.1. 検査タイプ別スニペット
3.2. 製品別スニペット
3.3. アプリケーション別スニペット
3.4. エンドユーザー別スニペット
3.5. 地域別スニペット
4. ダイナミクス
4.1. 影響要因
4.1.1. 推進要因
4.1.1.1. 感染症の増加
4.1.2. 阻害要因
4.1.2.1. 代替技術による脅威
4.1.3. 機会
4.1.4. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. サプライチェーン分析
5.3. 価格分析
5.4. 規制分析
5.5. 償還分析
5.6. 特許分析
5.7. SWOT分析
5.8. DMI意見
6. 検査タイプ別
6.1. はじめに
6.1.1. 検査タイプ別市場規模分析および前年比成長率分析(%)
6.1.2. 市場魅力度指数（検査タイプ別
6.2. ダイレクトELISA
6.2.1. 序論
6.2.2. 市場規模分析と前年比成長率分析(%)
6.3. 間接的ELISA
6.4. サンドイッチELISA
6.5. 競合ELISA法
7. 製品別
7.1. 製品紹介
7.1.1. 市場規模分析および前年比成長率分析（%）, 製品別
7.1.2. 市場魅力度指数（製品別
7.2. キット・試薬
7.2.1. はじめに
7.2.2. 市場規模分析と前年比成長率分析(%)
7.3. ELISA分析装置
7.3.1. 自動化
7.3.2. 半自動
8. アプリケーション別
8.1. 導入
8.1.1. 用途別市場規模分析および前年比成長率分析(%)
8.1.2. 市場魅力度指数、用途別
8.2. 創薬*市場
8.2.1. はじめに
8.2.2. 市場規模分析と前年比成長率分析(%)
8.3. 感染症
8.4. がん検出
8.5. タンパク質定量
8.6. その他
9. エンドユーザー別
9.1. 導入
9.1.1. 市場規模分析および前年比成長率分析（%）, エンドユーザー別
9.1.2. 市場魅力度指数（エンドユーザー別
9.2. 病院*市場
9.2.1. 導入
9.2.2. 市場規模分析と前年比成長率分析(%)
9.3. 学術・研究機関
9.4. 製薬・バイオテクノロジー企業
9.5. 診断研究所
9.6. その他
10. 地域別
10.1. はじめに
10.1.1. 地域別市場規模分析および前年比成長率分析(%)
10.1.2. 市場魅力度指数、地域別
10.2. 北米
10.2.1. 序論
10.2.2. 地域別主要市場
10.2.2.1. 市場規模分析および前年比成長率分析（%）、検査タイプ別
10.2.2.2. 市場規模分析および前年比成長率分析（%）、製品別
10.2.2.3. 市場規模分析および前年比成長率分析(%)、用途別
10.2.2.4. 市場規模分析および前年比成長率分析 (%)、エンドユーザー別
10.2.3. 市場規模分析および前年比成長率分析(%)、国別
10.2.3.1. 米国
10.2.3.2. カナダ
10.2.3.3. メキシコ
10.3. ヨーロッパ
10.3.1. はじめに
10.3.2. 地域別主要市場
10.3.2.1. 市場規模分析および前年比成長率分析（%）、検査タイプ別
10.3.2.2. 市場規模分析および前年比成長率分析（%）、製品別
10.3.2.3. 市場規模分析および前年比成長率分析(%)、用途別
10.3.2.4. 市場規模分析および前年比成長率分析(%)、エンドユーザー別
10.3.3. 市場規模分析および前年比成長率分析(%)、国別
10.3.3.1. ドイツ
10.3.3.2. イギリス
10.3.3.3. フランス
10.3.3.4. イタリア
10.3.3.5. スペイン
10.3.3.6. その他のヨーロッパ
10.4. 南米
10.4.1. はじめに
10.4.2. 地域別主要市場
10.4.2.1. 市場規模分析および前年比成長率分析（%）（検査タイプ別
10.4.2.2. 市場規模分析および前年比成長率分析（%）、製品別
10.4.2.3. 市場規模分析および前年比成長率分析(%)、用途別
10.4.3. 市場規模分析および前年比成長率分析 (%)、エンドユーザー別
10.4.4. 市場規模分析および前年比成長率分析(%)、国別
10.4.4.1. ブラジル
10.4.4.2. アルゼンチン
10.4.4.3. その他の南米諸国
10.5. アジア太平洋
10.5.1. 序論
10.5.2. 主な地域別ダイナミクス
10.5.2.1. 市場規模分析および前年比成長率分析（%）、検査タイプ別
10.5.2.2. 市場規模分析および前年比成長率分析（%）、製品別
10.5.2.3. 市場規模分析および前年比成長率分析(%)、用途別
10.5.3. 市場規模分析および前年比成長率分析 (%)、エンドユーザー別
10.5.4. 市場規模分析および前年比成長率分析(%)、国別
10.5.4.1. 中国
10.5.4.2. インド
10.5.4.3. 日本
10.5.4.4. 韓国
10.5.4.5. その他のアジア太平洋地域
10.6. 中東・アフリカ
10.6.1. 序論
10.6.2. 地域別主要市場
10.6.2.1. 市場規模分析および前年比成長率分析（%）、検査タイプ別
10.6.2.2. 市場規模分析および前年比成長率分析（%）、製品別
10.6.2.3. 市場規模分析および前年比成長率分析(%)、用途別
10.6.3. 市場規模分析および前年比成長率分析 (%)、エンドユーザー別
11. 競合情勢
11.1. 競争シナリオ
11.2. 市場ポジショニング／シェア分析
11.3. M&A分析
12. 企業プロフィール
12.1. Thermo Fisher Scientific, Inc.*
12.1.1. 会社概要
12.1.2. 製品ポートフォリオと内容
12.1.3. 財務概要
12.1.4. 主な展開
12.2. American Laboratory Products Company (ALPCO)
12.3. ZEUS Scientific, Inc.
12.4. Life Technologies Corporation
12.5. Bio-Rad Laboratories, Inc.
12.6. QuidelOrtho Corporation
12.7. bioMerieux S.A.
12.8. Gemelli Biotech
12.9. BD
12.10. Enzo Biochem Inc.
リストは網羅的ではありません
13. 付録
13.1. 会社概要とサービス
13.2. お問い合わせ
Global enzyme-linked immunosorbent assay market reached US$ 2.14 billion in 2023 and is expected to reach US$ 3.35 billion by 2031, growing at a CAGR of 5.8% during the forecast period 2024-2031.
Enzyme-linked Immunosorbent Assay is useful for detecting and estimating hormone levels such as human chorionic gonadotropin (HCG), follicle-stimulating hormone (FSH), and testosterone, as well as tracking disease outbreaks in communities such as chlamydia or influenza (the flu), and screening blood donations for possible viral components such as HIV. It detects nonmedical drug usage, such as the presence of amphetamines and cocaine in the body.
Rising infectious diseases globally are expected to drive the demand for enzyme-linked immunosorbent assay tests due to their specificity and identification of the antibodies. For instance, according to the World Health Organization's (WHO) 2024 Global Hepatitis Report, the number of deaths from viral hepatitis is rising. The disease is the second leading infectious cause of death in the world, accounting for 1.3 million deaths annually.
Market Dynamics: Drivers & Restraints
Increasing incidence of infectious diseases
The rising incidence of infectious diseases is expected to drive the enzyme-linked immunosorbent assay market growth. With the rising number of infectious diseases, there is a growing demand for enzyme-linked immunosorbent assay tests in laboratories. Antibodies against several infectious diseases such as Lyme disease, brucellosis, syphilis HIV and hepatitis among others can be detected and measured using ELISA.
Enzyme-linked immunosorbent assay is one of the most widely used diagnostic procedures for identifying antibodies, antigens, and other biomarkers linked to infectious illnesses. With the rising number of infectious diseases, government organizations, diagnostic centers and other laboratories depend on enzyme-linked immunosorbent assay for detecting the antibodies. There is a growing number of infectious diseases globally.
For instance, in 2022, the CDC received reports of about 63,000 cases of Lyme disease from state health agencies and the District of Columbia. This figure reflects cases recorded during routine national surveillance, which is simply one method used by public health professionals to track diseases. According to recent predictions utilizing alternative approaches, approximately 476,000 people in the United States will be identified and treated for Lyme disease each year. This number is likely to include patients treated based on clinical suspicion but do not have Lyme disease.
These infectious diseases, along with other diseases, require the utilization of enzyme-linked immunosorbent assay kits to detect antibodies and biomarkers. Thus, the increasing incidence of infectious diseases is expected to drive the Enzyme-Linked Immunosorbent Assay market growth.
Threat of substitution from alternative technologies
The chance of substitution from other technologies is a key obstacle to the growth and adoption of the ELISA (Enzyme-Linked Immunosorbent Assay) market. As innovative diagnostic and research technologies emerge, they provide benefits such as increased sensitivity, faster findings, and lower costs, potentially replacing or reducing the necessity for traditional ELISA assays. Thus, the above factors could hinder the enzyme-linked immunosorbent assay market
Segment Analysis
The global enzyme-linked immunosorbent assay market is segmented based on test type, product, application, end-user and region.
Sandwich ELISA segment is expected to dominate the enzyme-linked immunosorbent assay market share
The sandwich ELISA segment is expected to hold a major portion of the enzyme-linked immunosorbent assay market share. Sandwich ELISAs are the most common type of ELISA. The antigen is sandwiched between two specific antibodies, often known as matched antibody pairs. A microplate is covered with a capture antibody, a sample is added, and the protein of interest adheres to the plate and becomes immobilized.
A sandwich ELISA is more sensitive and robust because the antibody binds to two different sites on the antigen. This improves the binding selectivity of both the primary capture and detection antibodies to the antigen. The sandwich ELISA format is widely utilized due to its sensitivity and specificity.
New sandwich ELISA kits are being introduced into the market by several players which could contribute to the segment’s expansion. An increasing number of product launches could help drive the segment’s growth. For instance, in June 2024, ArcticZymes Technologies launched its SAN HQ 2.0 ELISA kit. This traditional sandwich ELISA is designed to detect and quantify the SAN HQ 2.0 enzyme in samples taken from the manufacturing stages of a complicated biomanufacturing process, such as the creation of viral vectors.
Thus, the sandwich ELISA segment is expected to hold the major portion of the enzyme-linked immunosorbent assay market share with the increasing innovation of new sandwich ELISA kits and their effectiveness in finding antibodies over other types of tests.
Geographical Analysis
North America is expected to hold a significant position in the enzyme-linked immunosorbent assay market share
North America is expected to hold a dominant position in the enzyme-linked immunosorbent assay market share owing to the increasing innovation of technological products, increasing research and development, the presence of a large number of key market players, and the rising incidence of infectious diseases. The region has highly equipped laboratories and it will invest more in the R&D department.
Several key players introduce a wide range of enzyme-linked immunosorbent assay products and kits with advanced features which could expand the region’s market expansion. For instance, on February 13, 2023, Charles River Laboratories International, Inc. launched its first Enzyme-Linked Immunosorbent Assay (ELISA) Kit for the detection and quantitation of residual host cell proteins (HCP) in CHO-based biotherapeutics.
Similarly, on May 24, 2022, Molecular Devices, LLC. unveiled five ready-made workcells for enzyme-linked immunosorbent assay (ELISA) workflows, with automation capabilities ranging from entry-level to advanced. Automation of labor-intensive plate-based assays improves walkaway time, throughput, and reproducibility by lowering the number of common, repetitive, hands-on steps for researchers.
The introduction of advanced instruments and systems will increase the adoption of these enzyme-linked immunosorbent assay products by several laboratories, diagnostic centers and research institutes, which will increase the demand for the products and expand of region’s market as well. Several market players in the region invest huge resources in innovating enzyme-linked immunosorbent assay products. Thus, the above factors are expected to drive the region’s market growth.
Market Segmentation
By Test Type
• Direct ELISA
• Indirect ELISA
• Sandwich ELISA
• Competitive ELISA
By Product
• Kits & Reagents
• ELISA Analyzers
o Automated
o Semi-automated
By Application
• Drug Discovery
• Infectious Diseases
• Cancer Detection
• Protein Quantification
• Others
By End-user
• Hospitals
• Academic and Research Institutes
• Pharmaceutical & Biotechnology Companies
• Diagnostic Laboratories
• Others
By Region
• North America
o The U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Thermo Fisher Scientific, Inc., American Laboratory Products Company (ALPCO), ZEUS Scientific, Inc., Life Technologies Corporation, Bio-Rad Laboratories, Inc., QuidelOrtho Corporation, Biomerieux S.A., Gemelli Biotech, BD
and Enzo Biochem Inc. among others.
Why Purchase the Report?
• To visualize the global enzyme-linked immunosorbent assay
Market Segmentation based on test type, product, application, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of enzyme-linked immunosorbent assay market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global enzyme-linked immunosorbent assay market report would provide approximately 53 tables, 47 figures, and 176 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Test Type
3.2. Snippet by Product
3.3. Snippet by Application
3.4. Snippet by End-user
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing incidence of infectious diseases
4.1.2. Restraints
4.1.2.1. Threat of substitution from alternative technologies
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. By Test Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
6.1.2. Market Attractiveness Index, By Test Type
6.2. Direct ELISA*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Indirect ELISA
6.4. Sandwich ELISA
6.5. Competitive ELISA
7. By Product
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
7.1.2. Market Attractiveness Index, By Product
7.2. Kits & Reagents*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. ELISA Analyzers
7.3.1. Automated
7.3.2. Semi-automated
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Drug Discovery*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Infectious Diseases
8.4. Cancer Detection
8.5. Protein Quantification
8.6. Others
9. By End-user
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
9.1.2. Market Attractiveness Index, By End-user
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Academic and Research Institutes
9.4. Pharmaceutical & Biotechnology Companies
9.5. Diagnostic Laboratories
9.6. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.2.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
10.2.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.3.1. The U.S.
10.2.3.2. Canada
10.2.3.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.3.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
10.3.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.3.1. Germany
10.3.3.2. UK
10.3.3.3. France
10.3.3.4. Italy
10.3.3.5. Spain
10.3.3.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.4.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
10.4.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.4.1. Brazil
10.4.4.2. Argentina
10.4.4.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
10.5.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.4.1. China
10.5.4.2. India
10.5.4.3. Japan
10.5.4.4. South Korea
10.5.4.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
10.6.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Thermo Fisher Scientific, Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. American Laboratory Products Company (ALPCO)
12.3. ZEUS Scientific, Inc.
12.4. Life Technologies Corporation
12.5. Bio-Rad Laboratories, Inc.
12.6. QuidelOrtho Corporation
12.7. bioMerieux S.A.
12.8. Gemelli Biotech
12.9. BD
12.10. Enzo Biochem Inc.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us
*** 酵素結合免疫吸着測定法（ELISA）の世界市場に関するよくある質問(FAQ) ***
・酵素結合免疫吸着測定法（ELISA）の世界市場規模は？
→DataM Intelligence社は2023年の酵素結合免疫吸着測定法（ELISA）の世界市場規模を21.4億米ドルと推定しています。
・酵素結合免疫吸着測定法（ELISA）の世界市場予測は？
→DataM Intelligence社は2031年の酵素結合免疫吸着測定法（ELISA）の世界市場規模を33.5億米ドルと予測しています。
・酵素結合免疫吸着測定法（ELISA）市場の成長率は？
→DataM Intelligence社は酵素結合免疫吸着測定法（ELISA）の世界市場が2024年～2031年に年平均5.8%成長すると展望しています。
・世界の酵素結合免疫吸着測定法（ELISA）市場における主要プレイヤーは？
→「Thermo Fisher Scientific, Inc., American Laboratory Products Company (ALPCO), ZEUS Scientific, Inc., Life Technologies Corporation, Bio-Rad Laboratories, Inc., QuidelOrtho Corporation, Biomerieux S.A., Gemelli Biotech, BD, Enzo Biochem Inc. など ...」を酵素結合免疫吸着測定法（ELISA）市場のグローバル主要プレイヤーとして判断しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、最終レポートの情報と少し異なる場合があります。
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
